UNITED ~~STATES~~STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~March~~ September 3130, 2025

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________to _______

Commission File Number: 0-12697

Dynatronics Corporation

(Exact name of registrant as specified in its charter)

Utah	87-0398434
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

1200 Trapp Road, Eagan, Minnesota 55121~~(Address of principal executive offices, Zip Code)~~

(~~801)~~Address ~~5687000(Registrant's~~of ~~telephone~~principal ~~number~~executive offices, ~~including~~Zip ~~area code~~Code)

~~Securities registered pursuant to Section 12~~(b801) ~~of the Act:None Securities registered pursuant to Section 12(g) of the Exchange ActCommon Stock, no par value~~5687000

~~Indicate by check mark whether the registrant~~ (1)Registrant's ~~has~~telephone filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports)number, ~~and~~including ~~(2)~~area ~~has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No~~code)

~~Indicate~~Securities byregistered ~~check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted~~ pursuant to ~~Rule~~Section ~~405 of Regulation ST~~ 12(§b) ~~232.405~~ of ~~this chapter) during~~ the ~~preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No~~Act:

None

Securities registered pursuant to Section 12(g) of the Exchange Act

Common Stock, no par value

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation ST (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
☒ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a nonaccelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated Filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b2 of the Exchange Act). Yes ☐ No ☒

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date:

As of ~~May~~November 912, 2025, there were 1016,~~619~~048,~~543~~734 shares of the issuer's common stock outstanding.

DYNATRONICS ~~CORPORATION~~CORPORATIONFORM 10Q

~~FORM~~FOR ~~10QFOR~~ THE QUARTERLY PERIOD ENDED ~~March~~SEPTEMBER 3130, 2025 ~~TABLE OF CONTENTS~~

	Page
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements	2
Condensed Consolidated Balance Sheets (Unaudited)	2
Condensed Consolidated Statements of Operations (Unaudited)	3
Condensed Consolidated Statements of Stockholders' Equity (Unaudited)	4
Condensed Consolidated Statements of Cash Flows (Unaudited)	5
Notes to Condensed Consolidated Financial Statements (Unaudited)	6
Cautionary Note Regarding ForwardLooking Statements	9
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	9
Item 3. Quantitative and Qualitative Disclosures About Market Risk	12
Item 4. Controls and Procedures	12
PART II. OTHER INFORMATION
Item 1. Legal Proceedings	13
Item 1A. Risk Factors	13
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	13
Item 3. Defaults Upon Senior Securities	13
Item 4. Mine Safety Disclosures	13
Item 5. Other Information	13
Item 6. Exhibits	14
Signatures	15

TABLE OF CONTENTS

		Page

PART I. FINANCIAL INFORMATION

Item 1.	Financial Statements	2

	Condensed Consolidated Balance Sheets (Unaudited)	2

	Condensed Consolidated Statements of Operations (Unaudited)	3

	Condensed Consolidated Statements of Stockholders' Equity (Unaudited)	4

	Condensed Consolidated Statements of Cash Flows (Unaudited)	5

	Notes to Condensed Consolidated Financial Statements (Unaudited)	6

	Cautionary Note Regarding Forward-Looking Statements	10

Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	10

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	13

Item 4.	Controls and Procedures	13

PART II. OTHER INFORMATION

Item 1.	Legal Proceedings	14

Item 1A.	Risk Factors	14

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	14

Item 3.	Defaults Upon Senior Securities	14

Item 4.	Mine Safety Disclosures	14

Item 5.	Other Information	14

Item 6.	Exhibits	15

Signatures		16

Table of Contents

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

DYNATRONICS CORPORATION

Condensed Consolidated Balance Sheets

(Unaudited)

		March 31, 2025			June 30, 2024
		September 30, 2025			June 30, 2025
Assets
Current assets:
Cash and cash equivalents	$	~~174~~761,~~090~~748		$	~~483~~326,~~918~~344
Restricted cash		50,410			50,410
Trade accounts receivable, less allowance for credit losses of $70,485 and $48,997 as of March 31, 2025 and June 30, 2024, respectively		2,837,232			3,444,587
Trade accounts receivable, less allowance for credit losses of $42,185 and $60,347 as of September 30, 2025 and June 30, 2025, respectively		2,721,285			2,800,900
Other receivables		~~178~~57,~~514~~040			~~454~~186,~~390~~403
Inventories, net		54,~~466~~824,~~794~~123			5,~~593~~074,~~974~~348
Prepaid expenses		~~645~~603,~~230~~549			~~530~~515,~~356~~780
Total current assets		9,~~352~~018,~~270~~155			108,~~557~~954,~~635~~185
Property and equipment, net		1,~~622~~406,~~482~~035			1,~~969~~513,~~413~~872
Operating lease assets		2,~~446~~938,~~078~~284			23,~~831~~195,~~417~~211
Intangible assets, net		21,~~536~~327,~~250~~439			21,~~999~~431,~~975~~382
Goodwill		7,116,614			7,116,614
Other assets		313,988			344,292
Other assets		374,595			465,505
Total assets	$	15,003,901		$	15,438,942
Total assets	$	23,448,289		$	25,940,559
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$	3,~~699~~167,~~380~~812		$	23,~~712~~404,~~142~~121
Accrued payroll and benefits expense		~~302~~242,~~601~~595			~~566~~360,~~443~~893
Accrued expense		~~671~~776,~~861~~857			~~725~~878,~~727~~874
Warranty reserve		~~104~~100,~~803~~548			~~120~~105,~~677~~664
Line of credit		12,~~851~~604,~~198~~407			21,~~121~~996,~~667~~956
Current portion of finance lease liability		~~315~~324,~~975~~933			~~302~~320,~~998~~423
Current portion of deferred gain		150,448			150,448
Current portion of operating lease liability		1,~~069~~057,~~220~~991			1,~~004~~018,~~808~~696
Total current liabilities		8,~~165~~425,~~486~~591			78,~~704~~236,~~910~~075
Finance lease liability, net of current portion		1,~~190~~025,~~241~~503			1,~~428~~108,~~870~~448
Deferred gain, net of current portion		~~514~~438,~~030~~806			~~626~~476,~~866~~418
Operating lease liability, net of current portion		1,~~380~~889,~~605~~848			12,~~829~~185,~~608~~998
Other liabilities		~~175~~163,~~136~~806			~~189~~169,~~861~~799
Total liabilities		11,~~425~~943,~~498~~554			1112,~~780~~176,~~115~~738
Commitments and contingencies
Stockholders' equity:
Preferred stock, no par value: Authorized 50,000,000 shares; 3,351,000 shares issued and outstanding as of March 31, 2025 and June 30, 2024, respectively		7,980,788			7,980,788
Preferred stock, no par value: Authorized 50,000,000 shares; 3,351,000 shares issued and outstanding as of September 30, 2025 and June 30, 2025		7,980,788			7,980,788
Common stock, no par value: Authorized 100,000,000 shares; 8,810,332 shares and 5,308,519 shares issued and outstanding as of March 31, 2025 and June 30, 2024, respectively		35,632,036			35,087,825
Common stock, no par value: Authorized 100,000,000 shares; 13,177,495 shares and 10,619,543 shares issued and outstanding as of September 30, 2025 and June 30, 2025, respectively		35,976,967			35,793,417
Accumulated deficit		(3140,~~590~~897,~~033~~408	)		(2840,~~908~~512,~~169~~001	)
Total stockholders' equity		123,~~022~~060,~~791~~347			143,~~160~~262,~~444~~204
Total liabilities and stockholders' equity	$	2315,~~448~~003,~~289~~901		$	2515,~~940~~438,~~559~~942

See accompanying notes to condensed consolidated financial statements.

Table of Contents

DYNATRONICS CORPORATION

Condensed Consolidated Statements of Operations

(Unaudited)

		Three Months Ended						~~Nine Months Ended~~
		March 31,						March 31,
		September 30,
		2025			2024			~~2025~~			~~2024~~
Net sales	$	67,~~151~~024,~~516~~027		$	7,~~657~~602,~~846~~249		$	~~21,053,989~~		$	~~25,161,111~~
Cost of sales		5,~~055~~292,~~214~~398			5,~~840~~621,~~729~~442			~~16,332,361~~			~~19,218,072~~
Gross profit		1,~~096~~731,~~302~~629			1,~~817~~980,~~117~~807			~~4,721,628~~			~~5,943,039~~
Selling, general, and administrative expenses		21,~~040~~820,~~624~~092			2,~~389~~231,~~073~~803			~~6,583,478~~			~~7,656,196~~
Operating loss		(~~944~~88,~~322~~463	)		(~~571~~250,~~956~~996	)		~~(1,861,850~~	)		~~(1,713,157~~	)
Other expense:
Interest expense, net		(95103,~~410~~366	)		(~~109~~106,~~292~~348	)		~~(308,383~~	)		~~(299,418~~	)
Other income, net		40,670			-			39,000			-
Net other expense		(103,366	)		(106,348	)
Net other expense		(54,740	)		(109,292	)		(269,383	)		(299,418	)
Loss before income taxes		(191,829	)		(357,344	)
Loss before income taxes		(999,062	)		(681,248	)		(2,131,233	)		(2,012,575	)
Income tax provision		(10,028	)		(9,304	)
Income tax benefit (provision)		-			13,526			(9,304	)		2,783
Net loss	$	(201,857	)	$	(366,648	)
Net loss	$	(999,062	)	$	(667,722	)	$	(2,140,537	)	$	(2,009,792	)
Preferred stock dividend, in common stock, issued or to be issued		(183,550	)		(167,738	)
Preferred stock dividend, in common stock, issued or to be issued		(187,977	)		(183,668	)		(541,327	)		(571,971	)
Net loss attributable to common stockholders	$	(385,407	)	$	(534,386	)
Net loss attributable to common stockholders	$	(1,187,039	)	$	(851,390	)	$	(2,681,864	)	$	(2,581,763	)
Net loss per common share:
Net loss per common share:
Basic and diluted	$	(0.03	)	$	(0.09	)
Basic and diluted	$	(0.13	)	$	(0.17	)	$	(0.37	)	$	(0.57	)
Weighted average shares outstanding:
Weighted average shares outstanding:
Basic and diluted		13,034,261			5,890,394
Basic and diluted		8,793,057			4,878,512			7,302,201			4,553,847

See accompanying notes to condensed consolidated financial statements.

Table of Contents

DYNATRONICS CORPORATION

Condensed Consolidated Statements of Stockholders' Equity

(Unaudited)

	Common stock				Preferred stock				Accumulated			Totalstockholders’'
	Shares		Amount		Shares		Amount		deficit			equity
Balance at June 30, 2023	4,044,984	$	34,355,315		3,351,000	$	7,980,788	$	(25,479,577	)	$	16,856,526
Balance at June 30, 2024	5,308,519	$	35,087,825		3,351,000	$	7,980,788	$	(28,908,169	)	$	14,160,444
Stock-based compensation	13,399		19,173		-		-		-			19,173
Preferred stock dividend, in common stock, issued or to be issued	201,656		197,059		-		-		(197,059	)		-
Net loss	-		-		-		-		(330,654	)		(330,654	)
Balance at September 30, 2023	4,260,039		34,571,547		3,351,000		7,980,788		(26,007,290	)		16,545,045
Stock-based compensation	8,080		(3,848	)	-		-		-			(3,848	)
Preferred stock dividend, in common stock, issued or to be issued	262,718		191,244		-		-		(191,244	)		-
Net loss	-		-		-		-		(1,011,416	)		(1,011,416	)
Balance at December 31, 2023	4,530,837		34,758,943		3,351,000		7,980,788		(27,209,950	)		15,529,781
Stock-based compensation	10,154		(16,492	)	-		-		-			(16,492	)
Preferred stock dividend, in common stock, issued or to be issued	341,384		183,668		-		-		(183,668	)		-
Net loss	-		-		-		-		(667,722	)		(667,722	)
Balance at March 31, 2024	4,882,375		34,926,119		3,351,000		7,980,788		(28,061,340	)		14,845,567
Stock-based compensation	-		2,804		-		-		-			2,804
Preferred stock dividend, in common stock, issued or to be issued	426,144		158,902		-		-		(158,902	)		-
Net loss	-		-		-		-		(687,927	)		(687,927	)
Balance at June 30, 2024	5,308,519		35,087,825		3,351,000		7,980,788		(28,908,169	)		14,160,444
Stock-based compensation	12,000		1,200		-		-		-			1,200
Preferred stock dividend, in common stock, issued or to be issued	575,745		167,738		-		-		(167,738	)		-
Net loss	-		-		-		-		(366,648	)		(366,648	)
Balance at September 30, 2024	5,896,264		35,256,763		3,351,000		7,980,788		(29,442,555	)		13,794,996
Stock-based compensation	-		1,200		-		-		-			1,200
Preferred stock dividend, in common stock, issued or to be issued	1,359,299		185,612		-		-		(185,612	)		-
Net loss	-		-		-		-		(774,827	)		(774,827	)
Balance at Decemeber 31, 2024	7,255,563		35,443,575		3,351,000		7,980,788		(30,402,994	)		13,021,369
Balance at December 31, 2024	7,255,563		35,443,575		3,351,000		7,980,788		(30,402,994	)		13,021,369
Stock-based compensation	8,000		484		-		-		-			484
Preferred stock dividend, in common stock, issued or to be issued	1,546,769		187,977		-				(187,977	)		-
Net loss	-		-		-		-		(999,062	)		(999,062	)
Balance at March 31, 2025	8,810,332	$	35,632,036		3,351,000	$	7,980,788	$	(31,590,033	)	$	12,022,791
Stock-based compensation	-		485		-		-		-			485
Preferred stock dividend, in common stock, issued or to be issued	1,809,211		160,896		-		-		(160,896	)		-
Net loss	-		-		-		-		(8,761,072	)		(8,761,072	)
Balance at June 30, 2025	10,619,543		35,793,417		3,351,000		7,980,788		(40,512,001	)		3,262,204
Preferred stock dividend, in common stock, issued or to be issued	2,557,952		183,550		-		-		(183,550	)		-
Net loss	-		-		-		-		(201,857	)		(201,857	)
Balance at September 30, 2025	13,177,495	$	35,976,967		3,351,000	$	7,980,788	$	(40,897,408	)	$	3,060,347

See accompanying notes to condensed consolidated financial statements.

Table of Contents

DYNATRONICS CORPORATION

Condensed Consolidated Statements of Cash Flows

(Unaudited)

		Nine Months Ended March 31,
		Three Months Ended September 30,
		2025			2024
Cash flows from operating activities:
Net loss	$	(2201,~~140,537~~857	)	$	(2366,~~009,792~~648	)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization of property and equipment		~~372~~108,~~662~~204			~~520~~155,~~051~~245
Amortization of intangible assets		~~463~~103,~~725~~943			~~463~~154,~~725~~575
Loss on sale of property		5,330			41,389
Stock-based compensation		-			1,200
Stock-based compensation		2,884			(1,166	)
Change in allowance for credit losses		(18,162	)		(13,925	)
Change in allowance for credit losses		21,488			(71,999	)
Change in allowance for inventory obsolescence		27,865			(18,900	)
Change in allowance for inventory obsolescence		(25,941	)		151,390
Amortization of deferred gain on sale/leaseback		(37,612	)		(37,612	)
Amortization of deferred gain on sale/leaseback		(112,836	)		(112,836	)
Change in operating assets and liabilities:
Trade accounts receivable		~~585~~97,~~867~~777			77402,~~378~~776
Inventories		~~153~~222,~~121~~360			1141,~~067,812~~399
Prepaid expenses and other receivables		~~161~~41,~~002~~594			~~(771~~9,~~569~~664	)
Other assets		9030,~~910~~304			~~333~~30,~~530~~302
Accounts payable, accrued expenses, and other current liabilities		~~638~~(467,~~931~~733	)		(1357,~~542,806~~430	)
Net cash provided by (used in) operating activities		216,606			(1,854,893	)
Net cash (used in) provided by operating activities		(93,317	)		100,646
Cash flows from investing activities:
Purchase of property and equipment		(~~30,312~~296	)		~~(241,014~~-	)
Net cash used in investing activities		(~~30,312~~296	)		~~(241,014~~-	)
Cash flows from financing activities:
Principal payments on finance lease liability		(~~225~~78,~~653~~434	)		(~~213~~74,~~383~~169	)
Net change in line of credit		~~(270~~607,~~469~~451	)		2(231,~~352,038~~952	)
Net cash (used in) provided by financing activities		(496,122	)		2,138,655
Net cash provided by (used in) financing activities		529,017			(306,121	)
Net change in cash and cash equivalents and restricted cash		~~(309~~435,~~828~~404	)		42(205,~~748~~475	)
Cash and cash equivalents and restricted cash at beginning of the period		~~534~~376,~~328~~754			~~552~~534,~~870~~328
Cash and cash equivalents and restricted cash at end of the period	$	~~224~~812,~~500~~158		$	~~595~~328,~~618~~853
Supplemental disclosure of cash flow information:
Cash paid for interest	$	~~192~~67,~~172~~207		$	~~455~~66,~~932~~029
Supplemental disclosure of non-cash investing and financing activities
Preferred stock dividend, in common stock, issued or to be issued	$	~~541~~183,~~327~~550		$	~~571~~167,~~971~~738
Operating lease right-of-use assets obtained in exchange for lease obligations		~~467,842~~-			35464,~~366~~866

See accompanying notes to condensed consolidated financial statements.

Table of Contents

DYNATRONICS CORPORATION

Notes to Condensed Consolidated Financial Statements

(Unaudited)

~~March~~September 3130, 2025

Note 1. Presentation and Summary of Significant Accounting Policies

Description of Business

Dynatronics Corporation (the "Company," or "Dynatronics") is a leading medical device company committed to providing high-quality products designed to accelerate optimal health. The Company designs, manufactures, and sells a broad range of products for clinical use in physical therapy, rehabilitation, orthopedics, pain management, and athletic training. Through its distribution channels, Dynatronics markets and sells to orthopedists, physical therapists, chiropractors, athletic trainers, sports medicine practitioners, clinics, and hospitals.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements (the "Condensed Consolidated Financial Statements") have been prepared by the Company in accordance with generally accepted accounting principles in the United States ("GAAP") and pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC"). Certain information and footnote disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to the rules and regulations of the SEC. As such, these Condensed Consolidated Financial Statements should be read in conjunction with the Company's audited financial statements and accompanying notes included in its Annual Report on Form 10K for the fiscal year ended June 30, ~~2024~~2025 (the "Annual Report") filed with the SEC on ~~September~~October 2414, ~~2024~~2025. The Condensed Consolidated Balance Sheet at June 30, ~~2024~~2025, has been derived from the Annual Report.

The accounting policies followed by the Company are set forth in Part II, Item 8, Note 1, Basis of Presentation and Summary of Accounting Policies, of the Notes to Consolidated Financial Statements included in the Company's Annual Report. In the opinion of management, the Condensed Consolidated Financial Statements contain all adjustments, consisting only of normal recurring adjustments, necessary to present fairly the Company's financial position as of ~~March~~September 3130, 2025 and its results of operations and its cash flows for the periods presented. The results of operations for the first ~~nine~~three months of the fiscal year are not necessarily indicative of results for the full year or any future periods.

The Company's fiscal year begins on July 1 and ends on June 30 and references made to "fiscal year ~~2025~~2026" and "fiscal year ~~2024~~2025" refer to the Company's fiscal year ending June 30, ~~2025~~2026 and the fiscal year ended June 30, ~~2024~~2025, respectively.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods presented.

The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ materially from those estimates and assumptions.

Other Receivables

Other receivables consist of amounts due from the Company's contract manufacturer for raw materials components provided for use in the production of the Company's products. Payments are due from the Company's contract manufacturer based on the usage of raw material components.

~~Sublease~~Operating ~~Agreement~~ Segments

OnThe ~~January 28, 2025, the~~ Company ~~entered~~operates ~~into~~in aone ~~sublease~~line ~~agreement~~of ~~with~~business: ~~Ninety~~the ~~Nine~~development, ~~Technologies~~manufacturing, ~~LLC.~~marketing, ~~The~~and ~~agreement~~distribution ~~extends~~of ~~through~~a ~~December~~broad ~~31,~~line ~~2025,~~of ~~with~~medical aproducts ~~monthly~~for ~~rent~~the ~~of $19~~orthopedic,~~700,~~ physical therapy and ~~will~~similar ~~continue~~markets. onAs asuch, ~~month-to-month~~the ~~basis~~Company ~~thereafter~~has ~~unless~~only ~~terminated~~one byreportable ~~either~~operating ~~party~~segment.

Liquidity and Going Concern

The ~~decline~~Company ~~from~~evaluated ~~historical~~whether ~~sales~~there are conditions and ~~subsequent~~events, ~~decrease~~considered in ~~accounts~~the ~~receivable~~aggregate, ~~has~~that ~~limited~~raise substantial doubt about the Company's ability to ~~generate~~continue ~~cash~~as ~~from~~a ~~operations~~going ~~and~~concern ~~limited~~within ~~the~~one ~~availability~~year ofafter ~~capital from~~ the ~~asset~~date ~~based~~on ~~line~~which ofthis ~~credit.~~Quarterly ~~Due~~Report toon ~~this,~~Form ~~net~~10-Q ~~working~~is ~~capital~~filed. ~~has~~The ~~decreased~~Company ~~from~~incurred ~~$2,853,000~~significant asrecurring ofoperating ~~June~~losses ~~30,~~primarily ~~2024~~driven toby ~~$1,187,000~~continuous asdecline ofin ~~March 31~~revenues, ~~2025,~~recurring ~~which~~negative ~~has~~cash ~~created~~flows ~~substantial~~and ~~doubt~~continued ~~about~~reduction ~~the~~in ~~Company's ability to continue as a going concern~~liquidity.

InAs ~~response,~~of ~~management~~September ~~has~~30, ~~implemented~~2025, ~~plans to continue~~ the Company ashad a$761,748 ~~going~~in ~~concern~~cash and ~~believes~~cash ~~that eliminating non-essential positions across the enterprise~~equivalents, ~~reducing~~compared ~~expenses~~to ~~by approximately~~ $~~600~~326,~~000~~344 ~~for~~as ~~fiscal~~of ~~year~~June ~~2025 and approximately $1~~30,~~700,000~~ on2025. anThe ~~annualized~~decline ~~basis~~from ~~will~~historical ~~allow~~sales ~~the~~and ~~Company~~subsequent todecrease ~~continue~~in asaccounts areceivable ~~going concern. Additionally, management~~ has ~~optimized~~limited the ~~square~~Company's ~~footage~~ability ~~needed~~to ~~for~~generate ~~the~~cash ~~orthopedic~~from ~~bracing~~operations ~~business segment~~ and islimited ~~actively working to optimize~~ the ~~square~~availability ~~footage~~of ~~footprint~~capital ~~needed~~from ~~for~~ the ~~therapeutic~~asset ~~modalities~~based ~~business~~line ~~segment. Optimization~~ of ~~the~~credit. ~~square~~Due ~~footage~~to ~~footprint~~this, ~~for~~net ~~both~~working ~~segments~~capital ~~could~~has ~~yield~~decreased ~~cost~~from ~~savings of approximately~~ $~~600~~718,~~000~~110 ~~annually.~~as ~~Management is also working to reduce the amount~~ of ~~excess~~June ~~inventory~~30, ~~exposure~~2025 ~~by promoting discounted prices~~ to ~~convert the excess inventory to cash. The Company projects that these initiatives will reduce expenses~~$592,564 ~~thereby~~as ~~reducing ongoing liquidity needs to enable continuation~~ of ~~operations~~September ~~and compliance with the debt covenants for the foreseeable future. Although there are no guarantees that the Company will be successful~~30, ~~management believes such initiatives will enable it to continue as a going concern through at least the next twelve months~~2025.

The Company reported operating losses of approximately $88,000 and $251,000 for the three months ended September 30, 2025 and 2024, respectively. The Company's declining revenues, recurring operating losses and negative cash flows, and continued reduction in liquidity, raise substantial doubt about the Company's ability to continue as a going concern within one year after the issuance date of these condensed consolidated financial statements. The Company is in the process of creating a comprehensive plan to address these challenges to improve performance, including cost reduction initiatives, streamlining operational processes, pursuing new revenue streams through product diversification, and transitioning production of the majority of the Company's therapeutic modalities from a contract manufacturer to internal operations. This shift to in-house production aims to reduce costs by eliminating third-party markups, enhance quality control with direct oversight of manufacturing processes, and improve supply chain reliability to mitigate risks of disruptions. The Company is also evaluating the current inventory position and working to reduce the amount of excess inventory exposure by promoting discounted prices to convert the excess inventory to cash. The Company will continue to look to add to its sales efforts to further improve revenue, consider additional options to improve operating efficiency, and enhance liquidity. The Company believes that if it successfully implements the foregoing strategic actions, it has a chance to mitigate the factors giving rise to substantial doubt; however, there is no guarantee that it will successfully implement these strategic actions. As a result, substantial doubt remains regarding the Company's ability to continue as a going concern.

Table of Contents

In addition to the foregoing, recent tariff changes imposed by the U.S. and China have created increased risks and uncertainties surrounding the Company's future results of operations. The impact of tariffs in the first quarter of 2025 was not material. However, should universal tariffs be implemented as initially announced in April 2025, the Company anticipates a significant adverse impact on its future costs of revenue, which will impact its results of operations. Particularly, the U.S. import tariffs and the reciprocal measures by China, are expected to increase the Company's cost of goods sold. The Company anticipates that some of its suppliers will incur incremental tariff-related costs, which may be passed on to the Company. The extent and duration of the tariffs and the resulting impact on general economic conditions and on the business are uncertain and are expected to be impacted by various factors, such as negotiations between the U.S. and affected countries, the responses of other countries or regions, exemptions or exclusions that already exist or may be granted, availability and cost of alternative sources of the products and materials, and the Company's ability to offset the effects of any tariffs that might be imposed. In response to these risks and uncertainties, the Company has taken affirmative steps to stock adequate inventory of certain key products and components to service immediate orders and is proactively working with its suppliers to mitigate potential tariff-related costs.

Moreover, the continuing effects of uncertainties in the broader economic environment on the global supply chain, higher personnel costs, and changes to customer or product mix, could have an adverse effect on our liquidity and cash and we continue to evaluate and take action, as necessary, to preserve adequate liquidity and ensure that our business can continue to operate during these uncertain times. Additionally, we operate in a rapidly evolving and unpredictable business environment that may change the timing or amount of expected future cash receipts and expenditures. Accordingly, there can be no assurance that we will not be required to raise additional funds through the sale of assets, equity or debt securities or from credit facilities. Additional capital, if needed, may not be available on satisfactory terms, or at all.

As discussed in Note 5, the Company is a party to a Loan and Security Agreement which may provide additional operating capital to the Company.

Recent Accounting Pronouncements

In August 2020, the FASB issued ASU 202006, Debt-Debt with Conversion and Other Options (Subtopic 47020) and Derivatives and Hedging-Contracts in Entity's Own Equity (Subtopic 81540): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity, which is intended to simplify the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity's own equity. The guidance allows for either full retrospective adoption or modified retrospective adoption. The Company adopted the standard as of July 1, 2024 and the adoption of this guidance did not have a material impact on its condensed consolidated financial statements and related disclosures.

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280) - Improvements to Reportable Segment Disclosures, to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The amendments are effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is evaluating the impact the adoption of this guidance will have on its condensed consolidated financial statements and related disclosures.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740) -Improvements to Income Tax Disclosures, which is intended to enhance the transparency and decision usefulness of income tax disclosures. Public business entities are required to adopt for annual fiscal periods beginning after December 31, 2024 and early adoption is permitted. The Company is evaluating the impact the adoption of this guidance will have on its condensed consolidated financial statements and related disclosures.

In November 2024, the FASB issued ASU 2024-03, Comprehensive Income (Topic 220) - Disaggregation of Income Statement Expenses, to improve financial reporting by requiring disclosures in the notes to financial statements about specific types of expenses included in the expense captions presented on the face of the statement of operations. The requirements of the ASU are effective for annual reporting periods beginning after December 15, 2026, and for interim reporting periods beginning after December 15, 2027, with early adoption permitted. The requirements will be applied prospectively with the option for retrospective application. The Company is evaluating the impact the adoption of this guidance will have on its condensed consolidated financial statements and related disclosures.

In November 2024, the FASB issued ASU 2024-04, Debt-Debt with Conversion and Other Options (Subtopic 47020): Induced Conversions of Convertible Debt Instruments, which clarifies the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion. The requirements of the ASU are effective for annual reporting periods beginning after December 15, 2025, and for interim reporting periods within those annual reporting periods. The Company is evaluating the impact the adoption of this guidance will have on its condensed consolidated financial statements and related disclosures.

In July 2025, the FASB issued ASU 2025-05, Financial Instruments - Credit Losses (Topic 326) - Measurement of Credit Losses for Accounts Receivable and Contract Assets, to introduce a practical expedient to calculating current expected credit loss by assuming that the current conditions as of the balance sheet date will not change for the remaining life of the asset. This expedient can only be applied to current accounts receivable and current contract assets. This update is effective for annual reporting periods beginning after December 15, 2025 and interim periods within those annual periods, and this update is applied prospectively. Early adoption is permitted in both interim and annual periods in which financials have not been issued. The Company is evaluating the impact the adoption of this guidance will have on its consolidated financial statements and related disclosures.

The Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

Note 2. Net Loss per Common Share

Net loss per common share is computed based on the weighted average number of common shares outstanding and, when appropriate, dilutive potential common stock outstanding during the period. Stock options, convertible preferred stock and warrants are considered to be potential common stock. The computation of diluted net loss per common share does not assume exercise or conversion of securities that would have an antidilutive effect.

Basic net loss per common share is the amount of net loss for the period available to each weighted average share of common stock outstanding during the reporting period. Diluted net loss per common share is the amount of net loss for the period available to each weighted average share of common stock outstanding during the reporting period and to each share of potential common stock outstanding during the period, unless inclusion of potential common stock would have an antidilutive effect.

All outstanding options, warrants and convertible preferred stock for common shares are not included in the computation of diluted net loss per common share because they are antidilutive, which for the three months ended ~~March~~September 3130, 2025 and 2024, totaled ~~688,200 and~~ 670,200, ~~respectively,~~ and ~~for the nine months ended March 31, 2025 and 2024, totaled~~ 688,200 ~~and 670~~,~~200,~~ respectively.,

Note 3. Convertible Preferred Stock

As of ~~March~~September 3130, 2025, the Company had issued and outstanding a total of 1,992,000 shares of Series A 8% Convertible Preferred Stock ("Series A Preferred") and 1,359,000 shares of Series B Convertible Preferred Stock ("Series B Preferred"). The Series A Preferred and Series B Preferred are convertible into a total of 670,200 shares of common stock. Dividends payable on these preferred shares accrue at the rate of 8% per year and are payable quarterly in stock or cash at the option of the Company. The Company generally pays the dividends on the preferred stock by issuing shares of its common stock. The formula for paying these dividends using common stock in lieu of cash can change the effective yield on the dividend to more or less than 8% depending on the market price of the common stock at the time of issuance.

In ~~April~~October 2025, the Company paid $~~187~~183,~~977~~550 of preferred stock dividends with respect to the Series A Preferred and Series B Preferred that accrued during the three months ended ~~March~~September 3130, 2025, by issuing 12,~~809~~557,~~211~~952 shares of common stock.

Table of Contents

Note 4. Inventories

Inventories consisted of the following:

		March 31, 2025			June 30, 2024
		September 30, 2025			June 30, 2025
Raw materials	$	3,~~214~~211,~~439~~823		$	3,~~596~~261,~~287~~234
Work in process		~~309~~348,~~356~~432			~~315~~351,~~075~~510
Finished goods		21,~~506~~844,~~741~~859			2,~~272~~014,~~295~~729
Inventory reserve		(~~563~~580,~~742~~991	)		(~~589~~553,~~683~~125	)
	$	54,~~466~~824,~~794~~123		$	5,~~593~~074,~~974~~348

Note 5. Debt

As of ~~March~~September 3130, 2025 and June 30, ~~2024~~2025, the line of credit was $12,~~851~~604,~~198~~407 and $21,~~121~~996,~~667~~956, respectively.

On August 1, 2023, the Company entered into a Loan and Security Agreement (the "Loan Agreement") with Gibraltar Business Capital, LLC ("Lender"), to provide asset-based financing to the Company to be used for operating capital. Amounts available under the Loan Agreement (the "Revolving Loans") are subject to a borrowing base calculation of up to a maximum availability of $7,500,000 (the "Revolving Loan Commitment") and bear interest at SOFR plus 5.00%. The Company paid a closing fee of 1.00% of the Revolving Loan Commitment and the line is subject to a monthly unused line fee in an annualized amount equal to 0.50% on the difference between the Revolving Loan Commitment and the average outstanding principal balance of the Revolving Loans for such month. The maturity date is three years from the date of the promissory note evidencing the Revolving Loans, subject to extension in accordance with the terms of the Loan Agreement.

The Loan Agreement provides for revolving credit borrowings by the Company in an amount up to the lesser of the Revolving Loan Commitment and a borrowing base amount equal to the sum of stated percentages of eligible accounts receivable and inventory, less reserves, computed on a weekly basis.

The obligations of the Company under the Loan Agreement are secured by a first-priority security interest in substantially all of the assets of the Company (including, without limitation, accounts receivable, equipment, inventory and other goods, intellectual property, contract rights and other general intangibles, cash, deposit accounts, equity interests in subsidiaries and joint ventures, investment property, documents and instruments, and proceeds of the foregoing).

The Loan Agreement contains affirmative and negative covenants, including covenants that restrict the ability of the Company and its subsidiaries to, among other things, incur or guarantee indebtedness, incur liens, dispose of assets, engage in mergers and consolidations, make acquisitions or other investments, make changes in the nature of its business, and engage in transactions with affiliates. The Loan Agreement also contains financial covenants applicable to the Company and its subsidiaries, including a minimum fixed charge coverage ratio of 1.0 to 1.0 if excess availability is less than $1,000,000 of the borrowing base.

On September 16, 2025, the Company received a written notice of default and reservation of rights from the Lender asserting an event of default by the Company under the Loan Agreement for failure to comply with its fixed charge coverage ratio during a financial coverage trigger period. In the notice, the Lender reserved the right to exercise any and all remedies available to it in connection with such event of default. To date, the Lender has not elected to exercise any such rights, but it may do so at any time in its discretion.

Note 6. Related-Party Transactions

The Company leases office, manufacturing and warehouse facilities in Northvale, New Jersey, ~~and~~from ~~Eagan~~employees, ~~Minnesota from~~ shareholders, and entities controlled by shareholders; who were previously principals of businesses acquired by the Company. ~~The~~Prior ~~combined~~to ~~expenses~~April ~~associated~~2025, ~~with~~the ~~these~~Company ~~relatedparty~~also ~~transactions~~leased ~~totaled $348~~office,~~456~~ manufacturing and ~~$332,857~~warehouse ~~for~~facilities ~~the~~in ~~three~~Eagan, ~~months~~Minnesota ~~ended~~from ~~March~~employees, 31shareholders, ~~2025~~ and ~~2024~~entities by shareholders who were previously principals of businesses acquired by the Company; however, ~~respectively~~as of April 2025, ~~and~~the Minnesota facility is no longer associated with related parties. The combined expenses associated with these related-party transactions totaled $1189,~~033,368~~580 and $~~999~~337,~~795~~225 for the ~~nine~~three months ended ~~March~~September 3130, 2025 and 2024, respectively.

Note 7. Revenue

As of ~~March~~September 3130, 2025 and June 30, ~~2024~~2025, the net rebate liability was $~~222~~220,~~215~~191 and $~~263~~271,~~959~~551, respectively. The rebate liability is included in accrued expenses within the accompanying condensed consolidated balance sheets. As of ~~March~~September 3130, 2025 and June 30, ~~2024~~2025, the allowance for sales discounts was $87,~~490~~800 and $137,~~814~~936, respectively. The allowance for sales discounts is included in trade accounts receivable, less allowance for credit losses in the accompanying condensed consolidated balance sheets.

The following table disaggregates revenue by major product category for the three ~~and nine~~ months ended ~~March~~September 3130, 2025 and 2024, respectively:

Three Months Ended March 31,

Nine Months Ended March 31,

Three Months Ended September 30,

2025

2024

~~2025~~

~~2024~~

Physical Therapy and Rehabilitation Products

34,~~310~~161,~~768~~586

34,~~656~~218,~~363~~354

~~11,554,808~~

~~12,631,415~~

Orthopedic Soft Bracing Products

2,~~816~~835,~~762~~716

3,~~980~~356,~~170~~988

~~9,425,615~~

~~12,464,521~~

Other

2326,~~986~~725

2126,~~313~~907

~~73,566~~

~~65,175~~

67,~~151~~024,~~516~~027

7,~~657~~602,~~846~~249

~~21,053,989~~

~~25,161,111~~

Note 8. Subsequent Events

Effective as of April 1, 2025 ("Commencement Date"), the Company, as tenant, entered into a lease ("Lease") with Ninety-Nine Technologies, LLC, as landlord, to occupy 56,687 square-feet of the manufacturing facility located at 1200 Trapp Road, Eagan, Minnesota. The initial term of the Lease begins on the Commencement Date and continues for a period of thirty-nine calendar months, subject to an option to extend the term for one additional period of 36 calendar months in accordance with the terms thereof. Under the Lease, the Company is obligated to pay annual base rent for the first year of $481,840, increasing at 4% per annum over the term of the Lease, together with its proportionate share of certain operating expenses.

Table of Contents

Note 8. Segment Information

The Company operates in one operating segment, and therefore one reportable segment, focused on the development, manufacturing, marketing, and distribution of a broad line of medical products for the orthopedic, physical therapy and similar markets. This determination, that the Company operates as a single operating segment, is consistent with the financial information regularly reviewed by the Chief Operating Decision Maker ("CODM") for purposes of evaluating performance, allocating resources, and planning and forecasting future periods. The Company's Chief Executive Officer ("CEO") is the CODM.

The accounting policies for the single operating segment are the same as those described in "Note 1-Basis of Presentation and Summary of Significant Accounting Policies." The CODM uses net loss based on net loss that is reported on the condensed consolidated statement of operations to allocate resources (including employees, property, and financial resources), predominantly during the annual budget and forecasting process. Selling, general, and administrative expenses are the sole significant expense category reviewed by the CODM at the segment level; no other segment expenses are material or separately evaluated. All revenues are generated in the US.

Asset information is not reported to or reviewed by the CODM to allocate resources, and therefore, the Company has not disclosed asset information for its segment.

The following table presents segment revenue and significant expenses regularly reviewed by the CODM for the three months ended September 30, 2025 and 2024:

		Three Months Ended September 30,
		2025			2024
Net sales	$	7,024,027		$	7,602,249
Cost of sales		5,292,398			5,621,442
Gross profit		1,731,629			1,980,807

Selling, general, and administrative expenses		1,820,092			2,231,803
Operating loss		(88,463	)		(250,996	)

Other (expense) income:
Interest expense, net		(103,366	)		(106,348	)
Net other expense		(103,366	)		(106,348	)

Loss before income taxes		(191,829	)		(357,344	)

Income tax provision		(10,028	)		(9,304	)

Net loss	$	(201,857	)	$	(366,648	)

Accordingly, the Company manages its operations as a single operating and reportable segment, and the condensed consolidated financial statements and notes thereto are presented as a single reportable segment.

Table of Contents

CAUTIONARY NOTE REGARDING FORWARDLOOKING STATEMENTS

This report, including the disclosures contained in Part I Item 2 Management's Discussion and Analysis of Financial Condition and Results of Operations, contains "forwardlooking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These forwardlooking statements include, but are not limited to: any projections of net sales, earnings, or other financial items; any statements of the strategies, plans and objectives of management for future operations; expectations in connection with the Company's previously announced business optimization plan; any statements concerning proposed new products or developments; any statements regarding future economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing. Forwardlooking statements can be identified by their use of such words as "may," "will," "estimate," "intend," "continue," "believe," "expect," or "anticipate" and similar references to future periods.

We have based our forwardlooking statements on management's current expectations and assumptions about future events and trends affecting our business and industry that are subject to risks and uncertainties. Although we do not make forwardlooking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. Forwardlooking statements are subject to substantial risks and uncertainties that could cause our future business, financial condition, results of operations or performance to differ materially from our historical results or those expressed or implied in any forwardlooking statement contained in this report. These risks and uncertainties include, but are not limited to, uncertainties related to the broader economic environment affecting communities and businesses globally, including ours, as well as those factors described in the section "Risk Factors" included in Part I, Item 1A of our Annual Report on Form 10K for the fiscal year ended June 30, ~~2024~~2025, filed with the SEC, as well as in our other public filings with the SEC. Actual results may differ from projections as a result of these risks, additional risks and uncertainties of which we are currently unaware or which we do not currently view as material to our business.

You should read this report in its entirety, together with the documents that we file as exhibits to this report and the documents that we incorporate by reference into this report, with the understanding that our future results may be materially different from what we currently expect. The forwardlooking statements contained in this report are made as of the date of this report and we assume no obligation to update them after the date hereof to revise or conform such statements to actual results or to changes in our opinions or expectations. If we do update or correct any forwardlooking statements, investors should not conclude that we will make additional updates or corrections.

We qualify all of our forwardlooking statements by these cautionary statements.

The terms "we," "us," "Dynatronics," or the "Company" refer collectively to Dynatronics Corporation and its whollyowned subsidiaries, unless otherwise stated.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") is designed to provide a reader of our Unaudited Condensed Consolidated Financial Statements and Notes thereto that are contained in this quarterly report, with a narrative from the perspective of management. You should also consider this information with the information included in our Annual Report on Form 10K for the fiscal year ended June 30, ~~2024~~2025, and our other filings with the SEC, including our quarterly and current reports that we have filed since June 30, ~~2024~~2025 through the date of this report. In the following MD&A, we have rounded many numbers to the nearest one thousand dollars. These numbers should be read as approximate. All intercompany transactions have been eliminated. Our fiscal year ends on June 30. For example, reference to fiscal year 2025 refers to the year ending June 30, ~~2025~~2026. This report covers the three ~~and nine~~ months ended ~~March~~September 3130, 2025. Results of operations for the three ~~and nine~~ months ended ~~March~~September 3130, 2025 are not necessarily indicative of the results that may be achieved for the full fiscal year ending June 30, ~~2025~~2026.

Overview

Dynatronics is a leading medical device company committed to providing high-quality restorative products designed to accelerate achieving optimal health. The Company designs, manufactures, and sells a broad range of products for clinical use in physical therapy, rehabilitation, orthopedics, pain management, and athletic training. Through its distribution channels, Dynatronics markets and sells to orthopedists, physical therapists, chiropractors, athletic trainers, sports medicine practitioners, clinics, and hospitals. The Company's products are marketed under a portfolio of high-quality, well-known industry brands including Bird & Cronin, Solaris, Hausmann, PROTEAM, and Mammoth, among others. More information is available at www.dynatronics.com.

Results of Operations

Net Sales

Net sales decreased $1578,~~506,~~000, or ~~19.~~7.6% to $67,~~152~~024,000 for the quarter ended ~~March~~September 3130, 2025, compared to net sales of $7,~~658~~602,000 for the quarter ended ~~March~~September 3130, 2024. ~~Net sales decreased $4,107,000 or 16.3% to $21,054,000 for the nine months ended March 31, 2025, compared to net sales of $25,161,000 for the nine months ended March 31, 2024.~~ The yearoveryear decrease is attributable to a reduction in overall volume for OEM customers and a general reduction in demand for the orthopedic soft bracing product category.

Gross Profit

Gross profit for the quarter ended ~~March~~September 3130, 2025 decreased $~~721~~249,000, or 39about 12.76%, to $1,~~096~~732,000, or 1724.87% of net sales. By comparison, gross profit for the quarter ended ~~March~~September 3130, 2024 was $1,~~817~~981,000, or 2326.~~7% of net sales. Gross profit for the nine months ended March 31, 2025 decreased $~~1~~,221,000, or 20.6~~%, ~~to $4,722,000, or 22.4%~~ of net sales. ~~By comparison, gross profit for the nine months ended March 31, 2024 was $5,943,000, or 23.6% of net sales.~~ The decrease in gross profit as a percentage of net sales was driven primarily by the reduction in net sales aswe previously discussed.

Selling, General and Administrative Expenses

Selling, general and administrative ("SG&A") expenses decreased $~~348~~412,000, or 1418.65%, to $21,~~041~~820,000 for the quarter ended ~~March~~September 3130, 2025, compared to $2,~~389~~232,000 for the quarter ended ~~March~~September 3130, 2024. The decline in selling, general and administrative expenses was driven by a reduction in salaries and benefits and a reduction in other professional expenses.

910

~~SG&A~~Table ~~expenses~~of decreased $1,073,000, or 14.0%, to $6,583,000 for the nine months ended March 31, 2025, compared to $7,656,000 for the nine months ended March 31, 2024. The overall reduction in SG&A expenses was led by a reduction in salaries and benefits and a decrease in other professional expenses.Contents

Net Other Expense

Net other expense for the quarter ended ~~March~~September 3130, 2025, was $55103,000 compared to net other expense of $~~109~~106,000 for the quarter ended ~~March~~September 3130, 2024. ~~Net~~ ~~other expense for the nine months ended March 31, 2025, was $269,000 compared to net other expense of $299,000 for the nine months ended March 31, 2024.~~ The ~~year-over-year~~ decrease in net other expense ~~for the nine months ended March 31, 2025~~ is primarily due to ~~decreased~~a ~~interest~~lower ~~expense~~average ~~under~~outstanding ~~the~~balance ~~Company's~~on our line of credit, ~~and~~during anthe ~~increase~~current ofperiod ~~other~~compared ~~income~~to ~~recognized~~the inprior ~~2025~~year.

Income Tax ~~Benefit (~~Provision)

Income tax ~~benefit (~~provision) was $~~0 and $14~~10,000 ~~for the quarters ended March 31, 2025~~ and ~~2024, respectively, and (~~$9,000) ~~and $3,000~~ for the ~~nine~~quarters ~~months~~ ended ~~March~~September 3130, 2025 and 2024, respectively. See Liquidity and Capital Resources - Deferred Income Tax Assets below for more information.

Net Loss

Net loss for the quarter ended ~~March~~September 3130, 2025 was $~~999~~202,000 compared to a net loss of $~~668~~367,000 for the quarter ended ~~March~~September 3130, 2024. The $~~331~~165,000 ~~increase~~decrease in net loss was attributable toby a decrease ~~in gross profit~~ of $~~721~~412,000 in SG&A expenses and a decrease in ~~the~~net ~~income~~other ~~tax~~expense ~~benefit~~ of $143,000, partially offset by a decrease in gross profit of $~~348~~249,000 ~~in SG&A expenses~~ and a ~~decrease of~~ $551,000 increase in ~~net~~the ~~other~~income ~~expense~~tax provision.

Net loss for the nine months ended March 31, 2025 was $2,141,000 compared to a net loss of $2,010,000 for the nine months ended March 31, 2024. The $131,000 increase in net loss was attributable to a decrease in gross profit of $1,221,000 and a decrease in the income tax benefit of $12,000 offset by a decrease of $1,073,000 in SG&A expenses and a decrease of $30,000 in net other expense.

Net Loss Attributable to Common Stockholders

Net loss attributable to common stockholders ~~increased~~decreased $~~336~~149,000 to $1385,~~187,~~000 for the quarter ended ~~March~~September 3130, 2025 compared to $~~851~~534,000 for the quarter ended ~~March~~September 3130, 2024. The ~~increase~~decrease in net loss attributable to common stockholders for the quarter is due primarily to a $~~331~~165,000 ~~increase~~decrease in the net loss, ~~and~~partially offset by a $516,000 increase in the deemed dividends on convertible preferred stock and accretion of discounts. On a per share basis, basic and diluted net loss attributable to common stockholders was $0.1303 per share for the quarter ended ~~March~~September 3130, 2025, compared to $0.1709 per share for the quarter ended ~~March~~September 3130, 2024.

Net loss attributable to common stockholders increased $100,000 to $2,682,000 for the nine months ended March 31, 2025 compared to $2,582,000 for the nine months ended March 31, 2024. The increase in net loss attributable to common stockholders for the quarter is due primarily to a $131,000 increase in the net loss offset by a $31,000 decrease in the deemed dividends on convertible preferred stock and accretion of discounts. On a per share basis, basic and diluted net loss attributable to common stockholders was $0.37 per share for the nine months ended March 31, 2025, compared to $0.57 per share for the nine months ended March 31, 2024.

Liquidity and Capital Resources

We have historically financed operations through cash from operating activities, available cash reserves, draws against the line of credit, and proceeds from the sale of our equity securities. As of ~~March~~September 3130, 2025, we had $~~174~~762,000 in cash and cash equivalents, compared to $~~484~~326,000 as of June 30, ~~2024~~2025.

Working capital was $1593,~~187,~~000 as of ~~March~~September 3130, 2025, compared to working capital of $2718,~~853,~~000 as of June 30, ~~2024~~2025. The current ratio was 1.1 to 1 as of ~~March~~September 3130, 2025 and 1.41 to 1 as of June 30, ~~2024~~2025. Current assets were 3960.91% of total assets as of ~~March~~September 3130, 2025, and 4058.70% of total assets as of June 30, ~~2024. These factors raised substantial doubt regarding the Company's ability to continue as a going concern as of March 31,~~ 2025.

InThe ~~response~~Company has incurred significant recurring operating losses primarily driven by a continuous decline in revenues, ~~management~~recurring ~~has~~negative ~~implemented~~cash ~~plans~~flows, toand ~~continue~~continued ~~the~~reduction in liquidity. The Company asreported aoperating ~~going~~losses ~~concern~~of $88,000 and ~~believes~~$251,000 ~~that~~for bythe ~~focusing~~three onmonths ~~cost-control~~ended ~~initiatives~~September 30, 2025 and 2024, respectively. These events have raised substantial doubt about the Company's ~~can~~ability to continue as a going concern. The Company ~~has~~is ~~reduced~~in ~~non-essential~~the ~~positions~~process ~~across~~of ~~the~~creating ~~enterprise,~~a ~~resulting~~comprehensive inplan ato ~~reduction~~address inthese ~~expense~~challenges ofto ~~approximately~~improve ~~$600~~performance,~~000~~ ~~for~~including ~~fiscal~~cost ~~year~~reduction ~~2025~~initiatives, ~~and~~streamlining ~~approximately~~operational $1processes,~~700,000~~ onpursuing annew ~~annualized~~revenue ~~basis. Additionally~~streams through product diversification, ~~management~~and ~~has~~transitioning ~~optimized~~production of the ~~square~~majority ~~footage~~of ~~needed~~our ~~for~~therapeutic ~~the~~modalities ~~orthopedic~~from ~~bracing~~a ~~segment~~contract ~~and~~manufacturer isto ~~actively~~internal ~~working~~operations. toThis ~~optimize~~shift ~~the~~to ~~square~~in-house ~~footage~~production ~~footprint~~aims ~~needed~~to ~~for~~reduce ~~the~~costs ~~therapeutic~~by ~~modalities~~eliminating ~~business~~third-party ~~segment~~markups, ~~which~~enhance ~~could~~quality ~~yield~~control ~~additional~~with ~~expense~~direct ~~reductions~~oversight of ~~approximately~~manufacturing ~~$600~~processes,~~000~~ onand animprove ~~annualized~~supply ~~basis~~chain reliability to mitigate risks of disruptions. The Company is also evaluating the current inventory position and working to reduce the amount of excess inventory exposure by promoting discounted prices to convert the excess inventory to cash. The Company will continue to look to add to its sales efforts to further improve revenue, consider additional options to improve operating efficiency, and enhance liquidity. The Company believes that if it successfully implements the foregoing strategic actions, it has a chance to mitigate the factors giving rise to substantial doubt; however, there is no guarantee that it will successfully implement these strategic actions. As a result, substantial doubt remains regarding the Company's ability to continue as a going concern.

The Company has begun to realize the effects of these plans and expects continued effects to be realized in fiscal year 2025 and fiscal year 2026. Due to these actions, management forecasts that the Company will have sufficient liquidity to meet its obligations for the next twelve months from the date of the financial statements' issuance.

Line of Credit

Table of Contents

Cash and Cash Equivalents and Restricted Cash

Our cash and cash equivalents and restricted cash position ~~decreased~~increased $~~309~~435,000 to $~~225~~812,000 as of ~~March~~September 3130, 2025, compared to $~~534~~377,000 as of June 30, ~~2024~~2025. The primary ~~uses~~source of cash for the ~~nine~~three months ended ~~March~~September 3130, 2025 ~~included~~was $~~270~~607,000 ~~net~~provided ~~change~~on in the line of credit,. The primary uses of cash included $~~226~~78,000 of principal payments on finance lease liabilities, and $3093,000 of ~~purchases of property and equipment. The primary source of~~ cash ~~was~~used ~~$217,000~~in ~~of cash provided by~~ operating activities.

Trade Accounts Receivable, net

Trade accounts receivable, net of allowance for credit losses, decreased approximately $~~607~~80,000 or 172.69%, to $2,~~837~~721,000 as of ~~March~~September 3130, 2025, from $32,~~445~~801,000 as of June 30, ~~2024~~2025. The decrease was driven primarily by a reduction in overall revenue and differences in the timing of collections around the end date of each respective quarter. Trade accounts receivable represents amounts due from our customers including dealers and distributors that purchase our products for redistribution, medical practitioners, clinics, hospitals, colleges, universities, and sports teams. We believe that our estimate of the allowance for credit losses is adequate based on our historical experience and relationships with our customers. Accounts receivable are generally collected within approximately 40 days of invoicing.

Inventories, net

Inventories, net of reserves, decreased $~~127~~250,000 or 24.39%, to $54,~~467~~824,000 as of ~~March~~September 3130, 2025, compared to $5,~~594~~074,000 as of June 30, ~~2024~~2025. The decrease was primarily due to steps taken to adjust inventory management in ~~line~~response ~~with~~to ~~sales~~the ~~trends~~impact asof ~~safety~~the ~~stock~~uncertain ~~levels~~operating ~~for~~environment ~~key~~on ~~items~~the ~~are~~global ~~adjusted~~supply chain and right-sizing incoming material purchases to ~~sales~~match ~~trends~~demand. We believe that our allowance for inventory obsolescence is adequate based on our analysis of inventory, sales trends, and historical experience.

Accounts Payable

Accounts payable ~~increased~~decreased approximately $~~987~~236,000 or 366.49%, to $3,~~699~~168,000 as of ~~March~~September 3130, 2025, from $23,~~712~~404,000 as of June 30, ~~2024~~2025. The ~~increase~~decrease was driven primarily by timing of payments.

Line of Credit

The outstanding balance of the line of credit was $12,~~851~~604,000 as of ~~March~~September 3130, 2025, compared to $21,~~122~~997,000 as of June 30, ~~2024~~2025.

Finance Lease Liability

Finance lease liability as of ~~March~~September 3130, 2025 and June 30, ~~2024~~2025 totaled approximately $1,~~506~~350,000 and $1,~~732~~429,000, respectively. Our finance lease liability consists primarily of our Utah building lease. In conjunction with the sale and leaseback of our Utah building in August 2014, we entered into a 15-year lease, classified as a finance lease, originally valued at $3,800,000. The building lease asset is amortized on a straightline basis over 15 years at approximately $252,000 per year. Total accumulated amortization related to the leased building is approximately $2,~~687~~813,000 at ~~March~~September 3130, 2025. The sale generated a profit of $2,300,000, which is being recognized ~~straight-line~~straightline over the life of the lease at approximately $150,000 per year as an offset to amortization expense. The balance of the deferred gain as of ~~March~~September 3130, 2025, is $~~664~~150,000. Lease payments, currently approximately $33,000, are payable monthly and increase annually by approximately 2% per year over the life of the lease. Imputed interest for the three ~~and nine~~ months ended ~~March~~September 3130, 2025 was approximately $2119,000 ~~and $66,000, respectively~~. In addition to the Utah building, we have certain equipment leases that we have determined are finance leases.

Operating Lease Liability

Operating lease liability as of ~~March~~September 3130, 2025 and June 30, ~~2024~~2025 totaled approximately $2,~~450~~948,000 and $23,~~834~~205,000, respectively. Our operating lease liability consists primarily of building leases for office, manufacturing, and warehouse space.

Deferred Income Tax Assets

A valuation allowance is required when there is significant uncertainty as to the realizability of deferred income tax assets. The ability to realize deferred income tax assets is dependent upon our ability to generate sufficient taxable income within the carryforward periods provided for in the tax law for each tax jurisdiction. We have determined that we do not meet the "more likely than not" threshold that deferred income tax assets will be realized. Accordingly, a valuation allowance is required. Any reversal of the valuation allowance in future periods will favorably impact our results of operations in the period of reversal. As of ~~March~~September 3130, 2025 and June 30, ~~2024~~2025, we recorded a full valuation allowance against our net deferred income tax assets.

Stock Repurchase Plans

We have a stock repurchase plan available to us at the discretion of the Board of Directors. Approximately $449,000 remained of this authorization as of ~~March~~September 3130, 2025. No purchases have been made under this plan since September 2011.

~~OffBalance~~Off-Balance Sheet Arrangements

As of ~~March~~September 3130, 2025, we had no ~~offbalance~~off-balance sheet arrangements.

1112

Table of Contents

Critical Accounting Policies

The preparation of our financial statements requires that we make estimates and judgments. We base these on historical experience and on other assumptions that we believe to be reasonable. Our critical accounting policies are discussed in Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations" section of our Annual Report on Form 10K for the fiscal year ended June 30, ~~2024~~2025. There have been no material changes to the critical accounting policies previously disclosed in that report.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

There have been no material changes from the information presented for the fiscal year ended June 30, ~~2024~~2025.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information that is required to be disclosed in our reports filed under the Securities Exchange Act of 1934, or Exchange Act, is recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to management, including our Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial and accounting officer), as appropriate, to allow timely decisions regarding any required disclosure. In designing and evaluating these disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures.

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the design and operation of our disclosure controls and procedures, as such term is defined under Rule 13a15(e) promulgated under the Exchange Act, as of ~~March~~September 3130, 2025. Based on this evaluation, our principal executive officer and principal financial officer concluded that as of ~~March~~September 3130, 2025, our disclosure controls and procedures were effective, at a reasonable assurance level, to ensure that information we are required to disclose in the reports we file or submit under the Exchange Act is (a) recorded, processed, summarized, and reported, within the time periods specified in the SEC's rules and forms and (b) accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) during the quarter ended ~~March~~September 3130, 2025, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

1213

Table of Contents

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

None.

Item 1A.

~~Except~~The ~~as set forth below, the~~ risk factors described in our Annual Report on Form 10K for the fiscal year ended June 30, ~~2024~~2025 have not materially changed.

Changes in U.S. and international trade policies, particularly with respect to China, may adversely impact our business and operating results.

Recent U.S. government actions have made significant changes to existing trade agreements and relationships between the U.S. and other countries. The U.S. government has implemented substantial changes in 2025 to U.S. trade policies, including import restrictions, increased import tariffs and changes in U.S. participation in multilateral trade agreements, such as the United States-Mexico-Canada Agreement to replace the former North American Free Trade Agreement.

The ongoing global economic competition and trade tensions between the U.S. and China has resulted in the U.S. government assessing supplemental tariffs on certain goods imported from China and China's assessment of retaliatory tariffs on certain imports of U.S. goods into China. It is unknown whether and to what extent new tariffs, export controls, or other new laws or regulations will be adopted, or the effect that any such actions would have on us or our industry.

Owing to the complex relationships between the U.S. and such other countries, political, diplomatic, military, or other events could result in business disruptions, including increased regulatory enforcement against companies, tariffs, trade embargoes, capital controls, export restrictions and the termination or modification of existing trade agreements. The imposition of such restrictions could increase the cost of the Company's products and the components and raw materials that go into making them, require the Company to change its operations and the products it offers and negatively impact consumer confidence and spending, all of which, both individually and in the aggregate, could materially and adversely affect our business, results of operations and financial condition.

The continuing worldwide macroeconomic and geopolitical uncertainty may adversely affect our business and prospects.

The United States and foreign countries have experienced recessionary pressures and face continued concerns about the systemic impacts of adverse economic conditions and geopolitical issues. Any negative impact on economic conditions and international markets, including increased geopolitical instability and other macroeconomic factors, including inflation, supply chain disruptions, interest rate and foreign currency rate fluctuations, and volatility in the capital markets could negatively impact our business, financial condition, and results of operations.

Continued concerns about the systemic impact of potential long-term and wide-spread recession and geopolitical issues, including wars, such as the war between Russia and Ukraine and the conflicts in the Middle East involving Israel, and acts of terrorism, have contributed to increased market volatility and diminished expectations for economic growth in the world. Our business and results of operations have been and may continue to be adversely impacted by changes in macroeconomic conditions, including inflation, rising interest rates, bank failures and the accessibility of capital markets. Uncertainty about global economic conditions may also cause decreased demand for our products and services and increased competition, which could result in lower sales volume and downward pressure on the prices for our products, longer sales cycles, and slower adoption of new technologies. A weakening of macroeconomic conditions may also adversely affect our suppliers, which could result in interruptions in supply and increased costs for the products we order from them.

Market acceptance of our medical products in the U.S. and other countries is dependent upon the medical equipment purchasing and procurement practices of our customers, patient need for our products and procedures and the reimbursement of patients' medical expenses by government healthcare programs and third-party payors. The continuing uncertainty surrounding global economic conditions and financial markets may cause the purchasers of medical equipment to decrease their procurement activities. Economic uncertainty, an increase in unemployment rates, as well as increasing health insurance premiums, co-payments and deductibles may adversely affect demand for our products and procedures. Furthermore, governments and other third-party payors around the world facing tightening budgets could move to further reduce the reimbursement rates or the scope of coverage offered, which could adversely affect the sales of our products.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

None.

Item 5. Other Information

During the fiscal quarter ended ~~March~~September 3130, 2025, none of our directors or officers informed us of the adoption , modification or termination of a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as those terms are defined in Regulation S-K, Item 408.

Item 6. Exhibits

10.1	Lease Agreement dated effective as of April 1, 2025 between Bird & Cronin, LLC and Ninety-Nine Technologies, LLC (incorporated by reference to Exhibit 10.1 of registrant's Current Report on Form 8-K filed April 4, 2025)
31.1	Certification under Rule 13a14(a)/15d14(a) of principal executive officer
31.2	Certification under Rule 13a-14(a)/15d-14(a) of principal financial officer
32.1	Certification under Section 906 of the SarbanesOxley Act of 2002 (18 U.S.C. Section 1350) of principal executive officer
32.2	Certification under Section 906 of the SarbanesOxley Act of 2002 (18 U.S.C. Section 1350) of principal financial officer
101.INS	Inline XBRL Instance Document - the instance document does not appear in the Interactive Date File because its XBRL tags are embedded with the Inline XBRL document
101.SCH	Inline XBRL Taxonomy Extension Schema Document
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104	Cover Page Interactive Data File - formatted as Inline XBRL and contained in Exhibit 101

Table of Contents

Item 6. Exhibits

31.1	Certification under Rule 13a14(a)/15d14(a) of principal executive officer

31.2	Certification under Rule 13a-14(a)/15d-14(a) of principal financial officer

32.1	Certification under Section 906 of the SarbanesOxley Act of 2002 (18 U.S.C. Section 1350) of principal executive officer

101.INS	Inline XBRL Instance Document - the instance document does not appear in the Interactive Date File because its XBRL tags are embedded with the Inline XBRL document

101.SCH	Inline XBRL Taxonomy Extension Schema Document

101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document

104	Cover Page Interactive Data File - formatted as Inline XBRL and contained in Exhibit 101

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	DYNATRONICS CORPORATION
Date: May 12, 2025	By:	/s/ Brian D. Baker
Date: November 19, 2025	By:	/s/ Brian D. Baker
		Brian D. Baker
		President, Chief Executive Officer
		President, Chief Executive Officer and Chief Financial Officer(Principal Executive Officer, Principal Financial Officer, and Principal Accounting Officer)
		(Principal Executive Officer, Principal Financial Officer, and Principal Accounting Officer)

1516

Filing Compare · DYNATRONICS CORP